Driving impairment
This medicine may affect your ability to drive or use machines.
Leaflet SASTRAVI 50mg / 12.5mg / 200mg film-coated tablets
- Product code:
- W61570003
- Quantity:
- 100
- Indicated for:
- Parkinson's disease
- Route of administration:
- oral
- Substance:
- levodopa + carbidopa + entacapone (antiparkinsonian agents)
- ATC
- N04BA03 — Nervous system | Dopaminergic agents | Dopa and dopa derivatives
Precautions:
Dizziness / vertigo
This medicine may cause dizziness or vertigo.
Hypotension / fall risk
May lower blood pressure and increase the risk of falls.
Drowsiness / sedation
This medicine may cause drowsiness or reduced alertness.
Levodopa + Carbidopa + Entacapone is a combination medication used in the treatment of Parkinson's disease, particularly in patients experiencing motor fluctuations ('on-off' phenomena) associated with levodopa therapy. This combination enhances treatment efficacy and prolongs the duration of levodopa's action.
- Levodopa is a precursor of dopamine, which helps compensate for the dopamine deficiency in the brain.
- Carbidopa is a peripheral decarboxylase inhibitor that prevents levodopa from being converted into dopamine outside the brain, reducing side effects such as nausea.
- Entacapone is a COMT (catechol-O-methyltransferase) inhibitor that slows the breakdown of levodopa, extending its effect in the brain.
This combination is effective in alleviating symptoms such as tremors, muscle rigidity, bradykinesia (slowness of movement), and motor fluctuations. It is important to take the medication as prescribed by a doctor, with the dosage gradually adjusted to minimize side effects.
Side effects may include nausea, diarrhea, dizziness, drowsiness, urine discoloration (brown-orange), and, in rare cases, hallucinations or compulsive behaviors. Regular monitoring is essential to adjust the treatment based on the progression of the disease.
- Levodopa is a precursor of dopamine, which helps compensate for the dopamine deficiency in the brain.
- Carbidopa is a peripheral decarboxylase inhibitor that prevents levodopa from being converted into dopamine outside the brain, reducing side effects such as nausea.
- Entacapone is a COMT (catechol-O-methyltransferase) inhibitor that slows the breakdown of levodopa, extending its effect in the brain.
This combination is effective in alleviating symptoms such as tremors, muscle rigidity, bradykinesia (slowness of movement), and motor fluctuations. It is important to take the medication as prescribed by a doctor, with the dosage gradually adjusted to minimize side effects.
Side effects may include nausea, diarrhea, dizziness, drowsiness, urine discoloration (brown-orange), and, in rare cases, hallucinations or compulsive behaviors. Regular monitoring is essential to adjust the treatment based on the progression of the disease.
General data about SASTRAVI 50mg / 12.5mg / 200mg
- Substance:
- levodopa + carbidopa + entacapone
- Date of latest medicines list:
- 01-03-2022
- Product code:
- W61570003
- Concentration:
- 50mg / 12.5mg / 200mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 100
- Product type:
- Generic medicine
- Prescription status:
- P-6L — Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.
Pharmaceutical forms available for levodopa + carbidopa + entacapone
Concentrations available for levodopa + carbidopa + entacapone
- 100mg/25mg/200mg
- 125mg/31.25mg/200mg
- 150mg/37.5mg/200mg
- 175mg/43.75mg/200mg
- 200mg/50mg/200mg
- 20mg/5mg/20mg/ml
- 50mg/12.5mg/200mg
- 75mg/18.5mg/200mg
- 75mg/18.75mg/200mg